Ubs Asset Management Americas Inc Akero Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 71,451 shares of AKRO stock, worth $2.98 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
71,451
Previous 60,416
18.27%
Holding current value
$2.98 Million
Previous $1.73 Million
14.66%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AKRO
# of Institutions
210Shares Held
74.3MCall Options Held
321KPut Options Held
558K-
Wellington Management Group LLP Boston, MA7.38MShares$307 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY6.86MShares$286 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$252 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$233 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$218 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.93B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...